You would expect that to be positive news for IMU rather than VLA, with Axel Hoos being a director of IMU as well as his role at GSK. IMUs market cap is only a tenth of VLA's.
http://www.fiercebiotech.com/story/.../2015-06-18?utm_medium=nl&utm_source=internal
Add to My Watchlist
What is My Watchlist?